Clinicians face significant challenges in managing older patients, particularly those suffering from multiple comorbid states. Clinical guidelines are primarily generated using evidence from randomized controlled trials that investigate the effects of specific drugs for the treatment of individual diseases. However, the clinical complexity of the older multimorbid patient population typically prevents them from meeting the inclusion and exclusion criteria of randomized controlled trials. Consequently, there is a lack of robust evidence for treating this population safely and effectively. Additionally, traditional disease management typically follows a single disease approach to care that is not adapted to the needs of persons with multimorbidity where the potential for inappropriate polypharmacy, and unwanted effects is greatly increased.
These issues notwithstanding, the last decade has witnessed major advances in the discovery of novel biomarkers and druggable targets for age-related disease states, the identification of factors involved in the complex interplay between patient, drugs, and diseases, and the development of strategies for targeting inappropriate polypharmacy. These developments, in association with the recent rise in the use of artificial intelligence and machine learning, offer unprecedented opportunities for research in geriatric pharmacology and in the management of older patients.
Therefore, this is the right time to develop a new journal that is entirely focussed on aspects of pharmacology that are directly relevant to the needs of the older patient population. By considering a wide range of submissions in basic science, clinical research and qualitative studies, ‘Geriatric Pharmacology’ is uniquely placed to capture this exciting momentum.
Taylor & Francis are currently supporting a 100% APC discount for all authors until the end of 2024, plus VAT or other local taxes where applicable in your country. There is no submission charge.